Haematological Malignancies
Cross-source consensus on Haematological Malignancies from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Risks & contraindications
Other
Highlighted claims
- Adults with haematological malignancies receiving intensive chemotherapy with or without HCT are at high risk of organ failure. — Impact of an early warning system on the outcome of patients with haematological malignancies receiving high-dose chemotherapy with or without haematopoietic cell transplantation: a protocol of the ALHERT cluster randomised trial
- Around 15% of newly diagnosed AML patients and 10-20% of allogeneic HCT recipients require ICU admission during treatment. — Impact of an early warning system on the outcome of patients with haematological malignancies receiving high-dose chemotherapy with or without haematopoietic cell transplantation: a protocol of the ALHERT cluster randomised trial
- Treatment toxicity and infectious complications related to immunosuppression drive the risk of organ failure in this population. — Impact of an early warning system on the outcome of patients with haematological malignancies receiving high-dose chemotherapy with or without haematopoietic cell transplantation: a protocol of the ALHERT cluster randomised trial
- ICU admission in these patients is associated with about 40% in-hospital mortality and up to 60% 1-year mortality. — Impact of an early warning system on the outcome of patients with haematological malignancies receiving high-dose chemotherapy with or without haematopoietic cell transplantation: a protocol of the ALHERT cluster randomised trial
- Eligible participants include adults admitted for ALL induction therapy, first-cycle AML induction therapy, autologous HCT, or allogeneic HCT. — Impact of an early warning system on the outcome of patients with haematological malignancies receiving high-dose chemotherapy with or without haematopoietic cell transplantation: a protocol of the ALHERT cluster randomised trial